Compare Bristol-Myers Squibb Co (BMY) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares MBS ETF — how do they compare? Bristol-Myers Squibb Co trades at $59.01 (market cap $116.30B), while iShares MBS ETF trades at $93.84. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares MBS ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| BMY | MBB | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $96.91 |
52-Week Low | $42.60 | $92.46 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MBB, the iShares MBS ETF, trades at $93.26, down 0.49% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oversold oscillators suggest potential for a near-term bounce. Recent news highlights institutional activity, with some firms increasing stakes while others reduced positions. The ETF continues its dividend distributions, with the latest payment scheduled for July 2026.
The outlook for MBB is mixed, balancing a defensive income stream from mortgage-backed securities against interest rate sensitivity. The primary opportunity lies in its monthly dividend yield, appealing for income-focused investors. Key risks include Federal Reserve policy shifts impacting bond valuations and broader economic conditions affecting the housing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
